With this combination therapy (TZB+ATV), we can aim to directly improve the temporal trajectory of CRCC and to suppress tumor growth, through suppression of IL-6 and recovering apoptosis of cancer cells after chemotherapy, returning cognitive capability to the normal level (Fig 6B). Here, IL6 is linked to chromophobe renal cell carcinoma.